SD BioSensor (137310.KS)

Executive Summary

SD BioSensor Inc. (137310.KS) is a South Korean in vitro diagnostics company that achieved significant global scale during the COVID-19 pandemic as a major manufacturer of rapid antigen and PCR test kits. Post-pandemic, the company is navigating a revenue normalization phase, leveraging its extensive manufacturing base in South Korea and international facilities, as well as its broad product portfolio spanning rapid diagnostic tests, molecular diagnostics, and point-of-care systems. The company’s core focus remains on infectious disease testing, including tuberculosis, HPV, malaria, and dengue, with a growing emphasis on expanding its menu and geographic reach. With an integrated R&D, production, and sales model, SD BioSensor is well-positioned to capture new opportunities in the post-COVID diagnostics market, though near-term growth will depend on successful product launches and regulatory clearances beyond its pandemic-era portfolio.

Upcoming Catalysts (preview)

• Q4 2025Launch of multiplex respiratory panel for near-patient testing70% success
• Q2 2026FDA clearance for HPV self-collection diagnostic kit60% success
• Q3 2026Strategic distribution partnership for molecular diagnostics in emerging markets80% success